Table 2.
Cohort matched
| Total (n = 185) | SSRT (n = 90) | SRT (n = 95) | p-value | |
|---|---|---|---|---|
| TOT (n = 90) | SSRT (n = 45) | SRT (n = 45) | p-value | |
| Age median (IQR) | ||||
| 62 (59–72) | 71 (68–75) | 59 (56–61) | < 0.001 | |
| Gleason score | ||||
| ≤ 7 | 72 (80) | 37 (82.22) | 35 (77.78) | 0.79 |
| > 7 | 18 (20) | 8 (17.78) | 10 (22.22) | |
| Pathological T | ||||
| 2 | 57 (63.33) | 24 (53.33) | 33 (73.33) | 0.13 |
| 3 | 31 (34.44) | 19 (42.22) | 12 (26.67) | |
| Unknown | 2 (2.22) | 2 (4.44) | 0 (0) | |
| Pathological N | ||||
| 0 | 50 (55.56) | 27 (60) | 23 (51.11) | 0.63 |
| 1 | 4 (4.44) | 2 (4.44) | 2 (4.44) | |
| X | 35 (38.89) | 15 (33.33) | 20 (44.44) | |
| Unknown | 1 (1.11) | 1 (2.22) | 0 (0) | |
| PSA pre-median (IQR) | ||||
| 9 (6.2–12) | 9 (6.4–12.6) | 9 (6.3–11.5) | 1 | |
| Biochemical PSA median (IQR) | ||||
| 1.14 (0.4–2.1) | 1.03 (0.4–1.8) | 1.25 (0.4–2.3) | 0.67 | |
| Time to relapse < 36 months | ||||
| Yes | 52 (57.78) | 26 (57.78) | 26 (57.78) | 0.36 |
| No | 38 (42.22) | 19 (42.22) | 19 (42.22) | |
| Clinical PSA median (IQR) | ||||
| 1.14 (0.6–2.3) | 1.16 (0.7–1.9) | 1.1 (0.4–2.3) | 1 | |
| Hormonal therapy | ||||
| Yes | 32 (35.56) | 25 (55.56) | 7 (15.56) | < 0.001 |
| No | 58 (64.44) | 20 (44.44) | 38 (84.44) | |
Significant results are highlighted in bold
SSRT Stereotactic salvage radiation therapy, SRT Salvage radiation therapy